ferroptosis

Overview

Ferroptosis is a form of regulated cell death, distinct from apoptosis and necroptosis, defined by the iron-dependent accumulation of lipid peroxides in cellular membranes to lethal levels. Its central axis is the cystine/glutamate antiporter system xc− (SLC7A11/SLC3A2), which supplies the cysteine required for glutathione (GSH) synthesis, and glutathione peroxidase 4 (GPX4), the GSH-dependent enzyme that reduces phospholipid hydroperoxides to unreactive alcohols. Deplete GSH or inactivate GPX4 and peroxidized lipids go unreduced, whereupon labile ferrous iron propagates the peroxidation chain reaction through Fenton chemistry. A second, GSH-independent defense runs in parallel at the membrane: ferroptosis suppressor protein 1 (FSP1) regenerates reduced coenzyme Q10 as a radical-trapping antioxidant, which is why GPX4 inhibition alone does not kill every cell. Susceptibility is set further upstream by membrane composition, since acyl-CoA synthetase long-chain family member 4 (ACSL4) activates polyunsaturated fatty acids to acyl-CoAs that downstream acyltransferases esterify into phospholipids, and membranes rich in these species are the easiest to peroxidize. Iron-handling proteins such as ferritin light chain (FTL) govern the labile iron pool that drives the reaction, while the transcription factor NRF2, through targets including heme oxygenase 1 and SLC7A11, is the principal stress-responsive brake on the whole process, with reactive oxygen species and general oxidative stress serving as both its drivers and its readouts.

Because ferroptosis sits at the intersection of iron homeostasis, redox balance, and lipid metabolism, it has been implicated across oncology and neurology, and the therapeutic logic runs in opposite directions in the two. Many tumors evade ferroptosis by upregulating ferroptosis-suppressive programs, which makes forced induction attractive: sensitivity to GPX4 or system xc− disruption has been explored in triple-negative breast cancer, hepatocellular carcinoma, non-small cell lung cancer, and pulmonary sarcomatoid carcinoma, and ferroptosis-related gene signatures are being evaluated as prognostic and drug-sensitivity biomarkers alongside other regulated cell death modes such as cuproptosis. The pathway also shapes tumor immunity: CD8+ T cell–derived interferon gamma suppresses SLC7A11 and sensitizes tumor cells, linking ferroptosis to checkpoint inhibitor and anti-PD-1 response, while tumor-intrinsic suppression of it has been associated with immunotherapy resistance.

In the nervous system the same features that make ferroptosis useful against cancer make it pathogenic. Iron accumulation, lipid peroxidation, and oxidative stress accompany the amyloid beta and tau pathology of Alzheimer's disease and the α-synuclein–associated loss of dopaminergic neurons in Parkinson's disease, motivating ferroptosis inhibitors, iron chelation, and antioxidant nanotherapeutics as neuroprotective approaches. Comparable roles have been proposed in chronic kidney disease, metabolic dysfunction–associated steatotic liver disease, and epithelial injury in chronic obstructive pulmonary disease. In all of these the therapeutic goal is suppression rather than induction, which is the practical reason ferroptosis is pursued as a target from both directions at once.

Recent Publications Summary (latest 30 papers)

Recent ferroptosis research spans diverse therapeutic contexts, with emphasis on both ferroptosis induction as an anti-cancer strategy and ferroptosis modulation in degenerative and aging-related diseases. In oncology, ferroptosis induction has emerged as a promising therapeutic approach across multiple cancer types. Multiple studies demonstrated that suppression of ferroptosis regulators—particularly glutathione Peroxidase 4 (GPX4) and the SLC7A11/GPX4 antioxidant system—confers resistance to chemotherapy and immunotherapy, suggesting ferroptosis induction as a strategy to overcome treatment resistance 42560559Aug42550740Aug42318657Jun42361801Jun. Conversely, some tumors employ ferroptosis suppression through upregulation of ferroptosis-protective genes via transcriptional or post-translational mechanisms; for example, MYC-driven upregulation of FTH1 and GPX4 in colorectal cancer 42560559Aug, MRPS30-mediated stabilization of GPX4 in hepatocellular carcinoma 42542152Aug, and GALNT7-dependent suppression in non-small cell lung cancer 42318657Jun. These findings identify ferroptosis resistance mechanisms as potential therapeutic vulnerabilities.

A broad range of ferroptosis-inducing compounds and delivery platforms have been evaluated in preclinical models. Small-molecule natural products—including curcumin in papillary thyroid carcinoma 42550316Aug, atranorin in ovarian cancer 42496762Jul, noni fruit juice in gastric cancer 42132559May, and the repurposed anthelmintic nitazoxanide in triple-negative breast cancer 42371677Jun—induced ferroptosis by downregulating GPX4 and SLC7A11 or by disrupting iron homeostasis. Novel delivery vehicles have also been developed: lipid nanoparticle co-delivering GPX4-siRNA with iron regeneration systems 42528415Jul, polydopamine nanoparticles loaded with antioxidants for acute kidney injury 42435348Jul, plant-derived exosome-like nanovesicles for hepatocellular carcinoma 42209785May, and mitochondrion-targeted polydopamine nanomedicines for neurodegenerative disease 42159234May. These approaches leverage the iron-dependent and lipid peroxidation components of ferroptosis to achieve selective cell death or tissue protection.

Beyond cancer, emerging evidence implicates ferroptosis dysregulation in neurodegenerative and chronic diseases. Ferroptosis-associated iron accumulation, lipid peroxidation, and oxidative stress have been linked to Alzheimer's disease 42474555Jul and Parkinson's disease 42159234May42035924Apr, with blood-based ferroptosis biomarkers identified as potential disease progression predictors 42035924Apr. Ferroptosis has also been identified as a pathogenic driver in chronic obstructive pulmonary disease, focal cortical dysplasia (epilepsy), osteoarthritis, and age-related organ dysfunction; notably, hepatocyte Hedgehog signaling suppression of ferroptosis was shown to alleviate aging-driven metabolic dysfunction and secondary kidney injury 42154541May. Therapeutic approaches in these contexts have primarily focused on ferroptosis inhibition—for instance, polysaccharide-mediated inhibition of ferroptosis via gut microbiota-dependent mechanisms in hepatic fibrosis 42002330Apr, and IGF-1-mediated ferroptosis suppression in obesity-associated cardiomyopathy 41990905Apr—suggesting disease prevention rather than therapeutic induction.

Ferroptosis regulation has emerged as an intersection point with immunotherapy and cell death pathways broadly. Studies indicate that ferroptosis induction promotes immunogenic cell death and CD8+ T-cell infiltration, whereas ferroptosis suppression is associated with cold tumor microenvironments and immunotherapy resistance 42318657Jun42029800Apr41998294Apr. A small-molecule cocktail promoting astrocyte-to-neuron reprogramming demonstrated that ferroptosis inhibition improved neuronal conversion efficiency in hemorrhagic brain injury 42527413Jul, while engineered nanoparticles exploiting the high reactive oxygen species microenvironment of senescent cells to trigger ferroptosis achieved 98% clearance efficiency in vitro 41979153Apr. Machine-learning approaches have enabled integration of multi-omics data to construct ferroptosis-based prognostic signatures and identify novel biomarkers associated with patient outcomes and drug sensitivity in hepatocellular carcinoma and other malignancies 42338358Jun42550740Aug, positioning ferroptosis as both a tractable therapeutic target and a biomarker of disease state across oncologic and non-oncologic contexts.

What Changes, What Holds

1. tumor ferroptosis suppression proceeds through MYC-driven and post-translational stabilization of antioxidant proteins
REINFORCES MYC upregulation of FTH1/GPX4 in colorectal cancer, MRPS30-mediated GPX4 stabilization in hepatocellular carcinoma, and GALNT7-dependent suppression in lung cancer demonstrate convergent resistance mechanisms 42560559Aug42542152Aug. The baseline's account of tumor-intrinsic ferroptosis evasion gains specificity: resistance routes through distinct transcriptional and post-translational pathways both converging on GPX4, identifying these regulatory nodes as potential intervention targets that refine the generic strategy of forced induction.

2. Ferroptosis-inducing compounds and nanoparticle delivery systems operationalize the induction strategy across multiple cancer types
NEW DIRECTION curcumin, atranorin, and nitazoxanide induce ferroptosis across papillary thyroid carcinoma, ovarian cancer, and triple-negative breast cancer by disrupting established antioxidant nodes 42550316Aug42371677Jun. lipid nanoparticle co-delivering GPX4-siRNA, polydopamine nanoparticles, and plant-derived exosomes extend beyond preclinical concept to clinically relevant delivery platforms, enabling ferroptosis induction in difficult-to-target tissues and repurposing existing pharmaceuticals—roles the baseline does not address.

3. Ferroptosis dysregulation extends pathogenic roles to osteoarthritis, hepatic aging, and metabolic disease beyond established neurodegeneration focus
NEW DIRECTION Ferroptosis-driven pathology now encompasses focal cortical dysplasia, osteoarthritis, hepatic fibrosis, and obesity-associated cardiomyopathy; notably, Hedgehog signaling–mediated ferroptosis suppression in hepatocytes alleviated aging-driven metabolic dysfunction and secondary kidney injury 42154541May42002330Apr. This expands ferroptosis's disease relevance while establishing a tissue-specific bifurcation: ferroptosis inhibition as preventive strategy in age-related disease, inverting the induction-focused approach in oncology.

4. Ferroptosis induction actively drives immunogenic cell death and CD8+ T-cell infiltration rather than serving as a passive immunotherapy correlate
REINFORCES Ferroptosis induction promotes immunogenic cell death and CD8+ T-cell infiltration, while ferroptosis suppression associates with cold tumor microenvironments and immunotherapy resistance 42318657Jun42029800Apr. This clarifies mechanistic directionality: the baseline's emphasis on ferroptosis suppression as immune evasion now pairs with evidence that induction itself triggers anti-tumor immunity. Machine-learning-derived prognostic signatures represent methodological rather than mechanistic advance.

Overview update candidates: Specific ferroptosis resistance mechanisms in cancer; ferroptosis-inducing compounds and delivery platforms; ferroptosis pathology in aging-related and metabolic disease; and immunogenic cell death as the mechanism linking ferroptosis induction to immunotherapy response.